Therapeutic potential of antisense oligonucleotides in hematological malignancies.
Antisense oligonucleotides show manageable safety and biological activity in blood cancers, with larger trials underway to confirm clinical benefit.
This systematic review from a French academic group synthesizes clinical trial evidence for ASO therapy across MDS, AML, ALL, and CLL, concluding that early-phase data show manageable toxicity profiles and encouraging biological activity while phase II/III data are pending. The review highlights ASO platform advantages for personalized medicine and identifies delivery efficiency and off-target effects as key barriers requiring translational solutions.
What the study was
- Study design
- Systematic review
- Population
- Patients with AML, MDS, ALL, and CLL enrolled in published ASO clinical trials
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Biomedicine & Pharmacotherapy
Why it surfaced
Comprehensive review of ASO therapy in hematologic malignancies covering 4 major disease areas; useful for T1 watchlist tracking of emerging non-chemotherapy modalities.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.